Skip to main content
Videos

Treatment Selection and Dose Management With Tovorafenib in Recurrent Pediatric Low-Grade Glioma


Tobey MacDonald, MD, discusses the use of tovorafenib in a heavily pretreated patient with BRAF V600E–mutated pediatric low-grade glioma. He walks through his management of decreased hemoglobin and phosphorus levels, including a treatment hold, dose adjustments, and supplementation, and reflects on how FIREFLY-1 findings might have informed a different approach. The patient completed two years of treatment with sustained disease control, decreased tumor dimensions, and maintained or improved vision, with no progression four weeks after completing therapy.

Transcript:

I am Tobey MacDonald. I'm a pediatric neuro-oncologist, and I'm also the director of the pediatric neuro-oncology program at Children's Healthcare of Atlanta and Emory University. For my case, my patient has been treated for a cystic and solid BRAF V600E–mutated pilocytic astrocytoma of the hypothalamus and optic chiasm from the age of three to early teenage. In this case, there have been no metastases. No other molecular testing of the tumor was performed outside of the BRAF sequencing.

The patient's functional deficits consist of bitemporal hemianopia with seesaw nystagmus, left exotropia with dysconjugate gaze, a wide-based gait, panhypopituitarism with diabetes insipidus, and developmental delay. My patient underwent subtotal tumor resection with VP shunt placement at diagnosis. Following that, there have been multiple shunt revisions, and her first treatment consisted of 52 weeks of carboplatin and vincristine at diagnosis per the CCG A9952 regimen A.

Her first tumor progression occurred four months after the completion of this regimen. And at that time, I switched treatment onto a phase 2 study with poly-ICLC, which the patient completed two full years with stable disease. However, a second tumor progression occurred approximately one and a half years after this, and the patient was treated with Avastin and irinotecan as a standard second-line therapy. But this was discontinued after seven months due to persistent hypertension.

I therefore changed treatment to dabrafenib, but this was also stopped after four months due to erythema nodosum, intermittent fevers, and joint pain and swelling. The tumor, however, did remain stable for about one and a half years after stopping this therapy before undergoing a third progression. At that time, I decided to treat the patient with Avastin and irinotecan again for 10 months before persistent hypertension recurred. Because of this persistent side effect, I elected to switch the patient at this time to tovorafenib to stabilize tumor growth and protect from further vision loss.

My patient completed two years of tovorafenib. I did, however, note that she underwent a decrease in her hemoglobin level from 13 to 11 grams per deciliter, and her phosphorus dropped from five to 2.7 milligrams per deciliter after one month of this treatment. At that time, without knowing the results of FIREFLY-1, I elected to hold tovorafenib for one week and resumed it at 50% dose, or 300 milligrams.

After starting phosphorus supplementation, I elected to increase the dose back to 400 milligrams after four months and then up to 500 milligrams after nine months, with stable hemoglobin and phosphorus levels. Because the MRI continued to show stable disease and her eye exam showed stable to improved vision at nine months on tovorafenib, I elected to keep the dose at 500 milligrams rather than escalate to the full dose of 600 milligrams. The patient did report some frequent headaches on tovorafenib, up to three to four times a week, which I understand is a known common side effect of this medication.

There were no growth delays observed and no adjustments to her hormonal replacement medications during the treatment. The best response observed was stable disease. However, there was almost a near partial response, with the tumor decreasing in size from a baseline of 2.1 by 1.4 centimeters to 1.8 by one centimeter after four months of treatment. And this was further stabilized and slightly decreased to 1.8 by 0.9 centimeters, continuing four weeks after completion of the tovorafenib therapy. Currently, the patient is stable and under ongoing observation.